Illegitimate V(D)J recombination involving nonantigen receptor loci in lymphoid malignancy

Genes Chromosomes and Cancer

Volumn 51, Issue 6, 2012, Pages 525-535

  Onozawa, Masahiro ^a   Aplan, Peter D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DOUBLE STRANDED DNA; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; IKAROS TRANSCRIPTION FACTOR; KRUPPEL LIKE FACTOR 6; LYMPHOCYTE ANTIGEN RECEPTOR; NOTCH1 RECEPTOR; RAG1 PROTEIN; RAG2 PROTEIN; TRANSCRIPTION FACTOR TAL1;

ACUTE LYMPHOCYTIC LEUKEMIA; APOPTOSIS; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL MATURATION; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; FUSION GENE; GENE LOCUS; GENE MUTATION; GENE SILENCING; GENETIC CODE; HEMATOPOIESIS; LYMPHOMA; MUTATION RATE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; VDJ RECOMBINATION;

ANIMALS; GENE DELETION; HUMANS; LEUKEMIA; MICE; V(D)J RECOMBINATION;

MAMMALIA; MURINAE; MUS;

EID: 84859441129     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.21942     Document Type: Review

References (75)

1. Akamatsu Y, Tsurushita N, Nagawa F, Matsuoka M, Okazaki K, Imai M, Sakano H. 1994. Essential residues in V(D)J recombination signals. J Immunol 153: 4520-4529.
2. Akira S, Okazaki K, Sakano H. 1987. Two pairs of recombination signals are sufficient to cause immunoglobulin V-(D)-J joining. Science 238: 1134-1138.
3. Albertini RJ. 2001. HPRT mutations in humans: biomarkers for mechanistic studies. Mutat Res 489: 1-16.
4. Aplan PD, Jones CA, Chervinsky DS, Zhao X, Ellsworth M, Wu C, McGuire EA, Gross KW. 1997. An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice. EMBO J 16: 2408-2419.
5. Aplan PD, Lombardi DP, Ginsberg AM, Cossman J, Bertness VL, Kirsch IR. 1990. Disruption of the human SCL locus by "illegitimate" V-(D)-J recombinase activity. Science 250: 1426-1429.
6. Aplan PD, Lombardi DP, Reaman GH, Sather HN, Hammond GD, Kirsch IR. 1992. Involvement of the putative hematopoietic transcription factor SCL in T-cell acute lymphoblastic leukemia. Blood 79: 1327-1333.
7. Ashworth TD, Pear WS, Chiang MY, Blacklow SC, Mastio J, Xu L, Kelliher M, Kastner P, Chan S, Aster JC. 2010. Deletion-based mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1. Blood 116: 5455-5464.
8. Aster JC, Pear WS, Blacklow SC. 2008. Notch signaling in leukemia. Annu Rev Pathol 3: 587-613.
9. Begley CG. 1994. The SCL transcription factor and differential regulation of macrophage differentiation by LIF, OSM and IL-6. Stem Cells 12: 143-149; discussion 149-151.
10. Begley CG, Green AR. 1999. The SCL gene: from case report to critical hematopoietic regulator. Blood 93: 2760-2770.
11. Begley CG, Aplan PD, Davey MP, Nakahara K, Tchorz K, Kurtzberg J, Hershfield MS, Haynes BF, Cohen DI, Waldmann TA, et al. 1989. Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor delta-chain diversity region and results in a previously unreported fusion transcript. Proc Natl Acad Sci USA 86: 2031-2035.
12. Brown L, Cheng JT, Chen Q, Siciliano MJ, Crist W, Buchanan G, Baer R. 1990. Site-specific recombination of the tal-1 gene is a common occurrence in human T cell leukemia. EMBO J 9: 3343-3351.
13. Chen CL, Fuscoe JC, Liu Q, Relling MV. 1996. Etoposide causes illegitimate V(D)J recombination in human lymphoid leukemic cells. Blood 88: 2210-2218.
14. Chen CL, Woo MH, Neale GA, Goorha RM, Fuscoe JC, Behm FG, Mathew S, Relling MV. 1998. A human lymphoid leukemia cell line with a V(D)J recombinase-mediated deletion of hprt. Mutat Res 403: 113-125.
15. Chervinsky DS, Zhao XF, Lam DH, Ellsworth M, Gross KW, Aplan PD. 1999. Disordered T-cell development and T-cell malignancies in SCL LMO1 double-transgenic mice: parallels with E2A-deficient mice. Mol Cell Biol 19: 5025-5035.
16. Chiang MY, Xu L, Shestova O, Histen G, L'Heureux S, Romany C, Childs ME, Gimotty PA, Aster JC, Pear WS. 2008. Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest 118: 3181-3194.
17. Delabesse E, Bernard M, Landman-Parker J, Davi F, Leboeuf D, Varet B, Valensi F, Macintyre EA. 1997. Simultaneous SIL-TAL1 RT-PCR detection of all tal(d) deletions and identification of novel tal(d) variants. Br J Haematol 99: 901-907.
18. Drexler HG. 1998. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 12: 845-859.
19. Dumortier A, Jeannet R, Kirstetter P, Kleinmann E, Sellars M, dos Santos NR, Thibault C, Barths J, Ghysdael J, Punt JA, Kastner P, Chan S. 2006. Notch activation is an early and critical event during T-Cell leukemogenesis in Ikaros-deficient mice. Mol Cell Biol 26: 209-220.
20. Ferrando AA. 2009. The role of NOTCH1 signaling in T-ALL. Hematology. Am Soc Hematol Educ Program 2009: 353-361.
21. Foster SA, Wong DJ, Barrett MT, Galloway DA. 1998. Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol Cell Biol 18: 1793-1801.
22. Furonaka O, Takeshima Y, Awaya H, Ishida H, Kohno N, Inai K. 2004. Aberrant methylation of p14(ARF), p15(INK4b) and p16(INK4a) genes and location of the primary site in pulmonary squamous cell carcinoma. Pathol Int 54: 549-555.
23. Fuscoe JC, Zimmerman LJ, Lippert MJ, Nicklas JA, O'Neill JP, Albertini RJ. 1991. V(D)J recombinase-like activity mediates hprt gene deletion in human fetal T-lymphocytes. Cancer Res 51: 6001-6005.
24. Gellert M. 1992. V(D)J recombination gets a break. Trends Genet 8: 408-412.
25. Georgopoulos K, Bigby M, Wang JH, Molnar A, Wu P, Winandy S, Sharpe A. 1994. The Ikaros gene is required for the development of all lymphoid lineages. Cell 79: 143-156.
26. Gutierrez A, Kentsis A, Sanda T, Holmfeldt L, Chen SC, Zhang J, Protopopov A, Chin L, Dahlberg SE, Neuberg DS, Silverman LB, Winter SS, Hunger SP, Sallan SE, Zha S, Alt FW, Downing JR, Mullighan CG, Look AT. 2011. The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. Blood 118: 4169-4173.
27. Herblot S, Steff AM, Hugo P, Aplan PD, Hoang T. 2000. SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-T alpha chain expression. Nat Immunol 1: 138-144.
28. Hesse JE, Lieber MR, Mizuuchi K, Gellert M. 1989. V(D)J recombination: a functional definition of the joining signals. Genes Dev 3: 1053-1061.
29. Iacobucci I, Storlazzi CT, Cilloni D, Lonetti A, Ottaviani E, Soverini S, Astolfi A, Chiaretti S, Vitale A, Messa F, Impera L, Baldazzi C, D'Addabbo P, Papayannidis C, Lonoce A, Colarossi S, Vignetti M, Piccaluga PP, Paolini S, Russo D, Pane F, Saglio G, Baccarani M, Foa R, Martinelli G. 2009. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood 114: 2159-2167.
30. Ikawa T, Hirose S, Masuda K, Kakugawa K, Satoh R, Shibano-Satoh A, Kominami R, Katsura Y, Kawamoto H. 2010. An essential developmental checkpoint for production of the T cell lineage. Science 329: 93-96.
31. Jeannet R, Mastio J, Macias-Garcia A, Oravecz A, Ashworth T, Geimer Le Lay AS, Jost B, Le Gras S, Ghysdael J, Gridley T, Honjo T, Radtke F, Aster JC, Chan S, Kastner P. 2010. Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL. Blood 116: 5443-5454.
32. Ji Y, Resch W, Corbett E, Yamane A, Casellas R, Schatz DG. 2010. The in vivo pattern of binding of RAG1 and RAG2 to antigen receptor loci. Cell 141: 419-431.
33. Kamimura K, Ohi H, Kubota T, Okazuka K, Yoshikai Y, Wakabayashi Y, Aoyagi Y, Mishima Y, Kominami R. 2007. Haploinsufficiency of Bcl11b for suppression of lymphomagenesis and thymocyte development. Biochem Biophys Res Commun 355: 538-542.
34. Kastner P, Chan S. 2011. Role of Ikaros in T-cell acute lymphoblastic leukemia. World J Biol Chem 2: 108-114.
35. Kitagawa Y, Inoue K, Sasaki S, Hayashi Y, Matsuo Y, Lieber MR, Mizoguchi H, Yokota J, Kohno T. 2002. Prevalent involvement of illegitimate V(D)J recombination in chromosome 9p21 deletions in lymphoid leukemia. J Biol Chem 277: 46289-46297.
36. Klein F, Feldhahn N, Herzog S, Sprangers M, Mooster JL, Jumaa H, Muschen M. 2006. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells. Oncogene 25: 1118-1124.
37. Kohno T, Yokota J. 1999. How many tumor suppressor genes are involved in human lung carcinogenesis? Carcinogenesis 20: 1403-1410.
38. Kuppers R, Dalla-Favera R. 2001. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 20: 5580-5594.
39. Li L, Leid M, Rothenberg EV. 2010. An early T cell lineage commitment checkpoint dependent on the transcription factor Bcl11b. Science 329: 89-93.
40. Lieber MR, Yu K, Raghavan SC. 2006. Roles of nonhomologous DNA end joining, V(D)J recombination, and class switch recombination in chromosomal translocations. DNA Repair (Amst) 5: 1234-1245.
41. Lin YW, Nichols RA, Letterio JJ, Aplan PD. 2006. Notch1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma. Blood 107: 2540-2543.
42. Marculescu R, Vanura K, Montpellier B, Roulland S, Le T, Navarro JM, Jager U, McBlane F, Nadel B. 2006. Recombinase, chromosomal translocations and lymphoid neoplasia: targeting mistakes and repair failures. DNA Repair (Amst) 5: 1246-1258.
43. Martinelli G, Iacobucci I, Storlazzi CT, Vignetti M, Paoloni F, Cilloni D, Soverini S, Vitale A, Chiaretti S, Cimino G, Papayannidis C, Paolini S, Elia L, Fazi P, Meloni G, Amadori S, Saglio G, Pane F, Baccarani M, Foa R. 2009. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol 27: 5202-5207.
44. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, White D, Hughes TP, Le Beau MM, Pui CH, Relling MV, Shurtleff SA, Downing JR. 2008a. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453: 110-114.
45. Mullighan CG, Williams RT, Downing JR, Sherr CJ. 2008b. Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. Genes Dev 22: 1411-1415.
46. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, Ma J, Liu W, Cheng C, Schulman BA, Harvey RC, Chen IM, Clifford RJ, Carroll WL, Reaman G, Bowman WP, Devidas M, Gerhard DS, Yang W, Relling MV, Shurtleff SA, Campana D, Borowitz MJ, Pui CH, Smith M, Hunger SP, Willman CL, Downing JR. 2009. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 360: 470-480.
47. Nagel S, Scherr M, Kel A, Hornischer K, Crawford GE, Kaufmann M, Meyer C, Drexler HG, MacLeod RA. 2007. Activation of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-cell acute lymphoblastic leukemia by remote 3′-BCL11B enhancers and coregulation by PU.1 and HMGA1. Cancer Res 67: 1461-1471.
48. Nakase K, Ishimaru F, Avitahl N, Dansako H, Matsuo K, Fujii K, Sezaki N, Nakayama H, Yano T, Fukuda S, Imajoh K, Takeuchi M, Miyata A, Hara M, Yasukawa M, Takahashi I, Taguchi H, Matsue K, Nakao S, Niho Y, Takenaka K, Shinagawa K, Ikeda K, Niiya K, Harada M. 2000. Dominant negative isoform of the Ikaros gene in patients with adult B-cell acute lymphoblastic leukemia. Cancer Res 60: 4062-4065.
49. Oettinger MA. 1999. V(D)J recombination: on the cutting edge. Curr Opin Cell Biol 11: 325-329.
50. Ohnishi H, Kawamura M, Ida K, Sheng XM, Hanada R, Nobori T, Yamamori S, Hayashi Y. 1995. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood 86: 1269-1275.
51. Orkin SH. 1995. Hematopoiesis: how does it happen? Curr Opin Cell Biol 7: 870-877.
52. Paganin M, Ferrando A. 2011. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev 25: 83-90.
53. Raghavan SC, Kirsch IR, Lieber MR. 2001. Analysis of the V(D)J recombination efficiency at lymphoid chromosomal translocation breakpoints. J Biol Chem 276: 29126-29133.
54. Rebollo A, Schmitt C. 2003. Ikaros, Aiolos and Helios: transcription regulators and lymphoid malignancies. Immunol Cell Biol 81: 171-175.
55. Sakata J, Inoue J, Ohi H, Kosugi-Okano H, Mishima Y, Hatakeyama K, Niwa O, Kominami R. 2004. Involvement of V(D)J recombinase in the generation of intragenic deletions in the Rit1/Bcl11b tumor suppressor gene in gamma-ray-induced thymic lymphomas and in normal thymus of the mouse. Carcinogenesis 25: 1069-1075.
56. Sherr CJ. 2000. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 60: 3689-3695.
57. Sun L, Liu A, Georgopoulos K. 1996. Zinc finger-mediated protein interactions modulate Ikaros activity, a molecular control of lymphocyte development. EMBO J 15: 5358-5369.
58. Sun L, Crotty ML, Sensel M, Sather H, Navara C, Nachman J, Steinherz PG, Gaynon PS, Seibel N, Mao C, Vassilev A, Reaman GH, Uckun FM. 1999a. Expression of dominant-negative Ikaros isoforms in T-cell acute lymphoblastic leukemia. Clin Cancer Res 5: 2112-2120.
59. Sun L, Goodman PA, Wood CM, Crotty ML, Sensel M, Sather H, Navara C, Nachman J, Steinherz PG, Gaynon PS, Seibel N, Vassilev A, Juran BD, Reaman GH, Uckun FM. 1999b. Expression of aberrantly spliced oncogenic ikaros isoforms in childhood acute lymphoblastic leukemia. J Clin Oncol 17: 3753-3766.
60. Sun L, Heerema N, Crotty L, Wu X, Navara C, Vassilev A, Sensel M, Reaman GH, Uckun FM. 1999c. Expression of dominant-negative and mutant isoforms of the antileukemic transcription factor Ikaros in infant acute lymphoblastic leukemia. Proc Natl Acad Sci USA 96: 680-685.
61. Tanigaki K, Honjo T. 2007. Regulation of lymphocyte development by Notch signaling. Nat Immunol 8: 451-456.
62. Thompson BJ, Buonamici S, Sulis ML, Palomero T, Vilimas T, Basso G, Ferrando A, Aifantis I. 2007. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 204: 1825-1835.
63. Tonnelle C, Imbert MC, Sainty D, Granjeaud S, N'Guyen C, Chabannon C. 2003. Overexpression of dominant-negative Ikaros 6 protein is restricted to a subset of B common adult acute lymphoblastic leukemias that express high levels of the CD34 antigen. Hematol J 4: 104-109.
64. Tsuji H, Ishii-Ohba H, Ukai H, Katsube T, Ogiu T. 2003. Radiation-induced deletions in the 5′ end region of Notch1 lead to the formation of truncated proteins and are involved in the development of mouse thymic lymphomas. Carcinogenesis 24: 1257-1268.
65. Tsuji H, Ishii-Ohba H, Katsube T, Ukai H, Aizawa S, Doi M, Hioki K, Ogiu T. 2004. Involvement of illegitimate V(D)J recombination or microhomology-mediated nonhomologous end-joining in the formation of intragenic deletions of the Notch1 gene in mouse thymic lymphomas. Cancer Res 64: 8882-8890.
66. Tsuji H, Ishii-Ohba H, Noda Y, Kubo E, Furuse T, Tatsumi K. 2009. Rag-dependent and Rag-independent mechanisms of Notch1 rearrangement in thymic lymphomas of Atm(-/-) and scid mice. Mutat Res 660: 22-32.
67. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, Gottardi E, Rambaldi A, Dotti G, Griesinger F, Parreira A, Gameiro P, Diaz MG, Malec M, Langerak AW, San Miguel JF, Biondi A. 1999. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13: 1901-1928.
68. Wakabayashi Y, Watanabe H, Inoue J, Takeda N, Sakata J, Mishima Y, Hitomi J, Yamamoto T, Utsuyama M, Niwa O, Aizawa S, Kominami R. 2003. Bcl11b is required for differentiation and survival of alphabeta T lymphocytes. Nat Immunol 4: 533-539.
69. Wang JH, Nichogiannopoulou A, Wu L, Sun L, Sharpe AH, Bigby M, Georgopoulos K. 1996. Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. Immunity 5: 537-549.
70. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT, Aster JC. 2004. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306: 269-271.
71. Wiencke JK, Zheng S, Lafuente A, Lafuente MJ, Grudzen C, Wrensch MR, Miike R, Ballesta A, Trias M. 1999. Aberrant methylation of p16INK4a in anatomic and gender-specific subtypes of sporadic colorectal cancer. Cancer Epidemiol Biomarkers Prev 8: 501-506.
72. Williams RT, Sherr CJ. 2008. The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias. Cold Spring Harb Symp Quant Biol 73: 461-467.
73. Winandy S, Wu P, Georgopoulos K. 1995. A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma. Cell 83: 289-299.
74. Yoshida T, Ng SY, Zuniga-Pflucker JC, Georgopoulos K. 2006. Early hematopoietic lineage restrictions directed by Ikaros. Nat Immunol 7: 382-391.
75. Zhang M, Swanson PC. 2008. V(D)J recombinase binding and cleavage of cryptic recombination signal sequences identified from lymphoid malignancies. J Biol Chem 283: 6717-6727.